DK1448236T3 - Inklusionskompleks af taxol med 2-hydroxypropyl-beta-cyclodextrin - Google Patents

Inklusionskompleks af taxol med 2-hydroxypropyl-beta-cyclodextrin

Info

Publication number
DK1448236T3
DK1448236T3 DK02783465T DK02783465T DK1448236T3 DK 1448236 T3 DK1448236 T3 DK 1448236T3 DK 02783465 T DK02783465 T DK 02783465T DK 02783465 T DK02783465 T DK 02783465T DK 1448236 T3 DK1448236 T3 DK 1448236T3
Authority
DK
Denmark
Prior art keywords
hydroxypropyl
beta
taxol
cyclodextrin
inclusion complex
Prior art date
Application number
DK02783465T
Other languages
English (en)
Inventor
Konstantinos Anastasi Kagkadis
Original Assignee
Vianex S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vianex S A filed Critical Vianex S A
Application granted granted Critical
Publication of DK1448236T3 publication Critical patent/DK1448236T3/da

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Epoxy Compounds (AREA)
DK02783465T 2001-11-19 2002-11-15 Inklusionskompleks af taxol med 2-hydroxypropyl-beta-cyclodextrin DK1448236T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0127677.3A GB0127677D0 (en) 2001-11-19 2001-11-19 Inclusion complex
PCT/IB2002/005058 WO2003043662A1 (en) 2001-11-19 2002-11-15 Inclusion complex of taxol with 2-hydroxypropyl-beta-cyclodextrin

Publications (1)

Publication Number Publication Date
DK1448236T3 true DK1448236T3 (da) 2007-03-05

Family

ID=9926016

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02783465T DK1448236T3 (da) 2001-11-19 2002-11-15 Inklusionskompleks af taxol med 2-hydroxypropyl-beta-cyclodextrin

Country Status (15)

Country Link
US (1) US7307176B2 (da)
EP (1) EP1448236B1 (da)
JP (1) JP4467978B2 (da)
CN (1) CN100425289C (da)
AT (1) ATE352321T1 (da)
AU (1) AU2002347533B2 (da)
CA (1) CA2467110C (da)
CY (1) CY1106331T1 (da)
DE (1) DE60217899T2 (da)
DK (1) DK1448236T3 (da)
ES (1) ES2278985T3 (da)
GB (1) GB0127677D0 (da)
NZ (1) NZ532964A (da)
PT (1) PT1448236E (da)
WO (1) WO2003043662A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
CN100486645C (zh) 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
EP2200649A4 (en) 2007-10-19 2012-09-26 Univ California COMPOSITIONS AND METHODS FOR TREATING CNS INFUSION, PSYCHOSIS, DELIRE, PTSD OR PTSS
KR101502533B1 (ko) * 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
US8623329B1 (en) * 2009-10-13 2014-01-07 Aerophase, Inc. Method for the treatment of lung tumors
JP5816896B2 (ja) * 2011-01-26 2015-11-18 ステラファーマ株式会社 カルボラン修飾コウジ酸/シクロデキストリン包接錯体およびその製造方法
CN102266568A (zh) * 2011-08-01 2011-12-07 扬州大学 一种紫杉醇的羟丙基环糊精包合物的制备方法
JP7138643B2 (ja) * 2017-01-09 2022-09-16 サイファーム ソシエテ ア レスポンサビリテ リミテ 水溶性フォルスコリンの新規製造法
CN110755371B (zh) 2018-07-25 2021-08-31 比卡生物科技(广州)有限公司 一种注射用多西他赛组合物及其制备方法
US20250121099A1 (en) * 2022-01-05 2025-04-17 The Regents Of The University Of California Closo-dodecaiododecaborate complexes and methods of use for same
CN115748013A (zh) * 2022-11-17 2023-03-07 东北农业大学 一种烯唑醇环糊精包合物纳米纤维及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5684169A (en) * 1992-11-27 1997-11-04 Ensuiko Sugar Refining Co., Ltd. Cyclodextrin inclusion complex of taxol, and method for its production and its use
JPH0753396A (ja) * 1993-08-19 1995-02-28 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物,その製造法および用途
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
DE19939662A1 (de) * 1999-08-20 2001-02-22 Stockhausen Chem Fab Gmbh Wasserabsorbierende Polymere mit Hohlraumverbindungen, Verfahren zur deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
DE60217899T2 (de) 2007-05-10
CY1106331T1 (el) 2011-10-12
US7307176B2 (en) 2007-12-11
EP1448236A1 (en) 2004-08-25
GB0127677D0 (en) 2002-01-09
ATE352321T1 (de) 2007-02-15
HK1068005A1 (en) 2005-04-22
CA2467110A1 (en) 2003-05-30
JP2005515982A (ja) 2005-06-02
WO2003043662A1 (en) 2003-05-30
JP4467978B2 (ja) 2010-05-26
CA2467110C (en) 2012-04-17
AU2002347533A1 (en) 2003-06-10
CN100425289C (zh) 2008-10-15
NZ532964A (en) 2005-09-30
ES2278985T3 (es) 2007-08-16
AU2002347533B2 (en) 2007-09-06
US20050009783A1 (en) 2005-01-13
DE60217899D1 (de) 2007-03-15
EP1448236B1 (en) 2007-01-24
PT1448236E (pt) 2007-02-28
CN1589157A (zh) 2005-03-02

Similar Documents

Publication Publication Date Title
CY1106331T1 (el) Κλειστο συμπλοκο της ταξολης με 2-υδροξυπροπυλ-βητα-κυκλοδεξτρινη
ATE263157T1 (de) Nematizide trifluorbutene
MA26344A1 (fr) Derives 1,8-naphtyridine utilises comme antidiabetiques
EA200300595A1 (ru) Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора
NO20035301D0 (no) Små molekyl¶re antagonister av proteiner i BCL-2-familien
ATE347906T1 (de) Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen
ECSP056111A (es) Derivados de 2-acilamino-4-feniltiazol, su preparación y aplicación en terapeutica
DE60018119D1 (de) Verfahren zur herstellung von polymorphen des clarithromycins
DE602004005323D1 (de) Azidfreies verfahren zur herstellung von 1,2-diaminoverbindungen
NO20033036D0 (no) Lökkefiltstoff, samt fremgangsmåte for tilvirking av dette
DE60206030D1 (de) Azofarbstoffe
DE50105968D1 (de) VERFAHREN ZUR HERSTELLUNG VON AlKYLVERBRÜCKTEN LIGANDSYSTEMEN UND ÜBERGANGSMETALLVERBINDUNGEN
NO20062699L (no) Smelteblandingsdispergeringer
TR200402546T4 (tr) Taksan türevleri hazırlamak için işlem.
WO2005040283A3 (en) Disperse azo dyestuffs
ATE281827T1 (de) Verwendung von esterquats
ATE312842T1 (de) Reduziertes cortisolkonjugat
DE602004025674D1 (de) Herstellung von 3,6-dichlor-2-trichlormethylpyridin durch dampfphasenchlorierung von 6-chlor-2-trichlormethylpyridin
DK1339703T3 (da) Fremgangsmåde til fremstilling af paclitaxel
Mailvaganam How chemical admixtures produce their effects in concrete?
Evans et al. Intermolecular Transition Metal-Catalyzed [4+ 2+ 2] Cycloaddition Reactions: A New Approach to the Construction of Eight-Membered Rings [J. Am. Chem. Soc. 2002, 124 (30), 8782− 8783].
RU2003115947A (ru) Средство для литолиза мочевых камней и способ его получения
ATE487943T1 (de) Fluoreszenzpolypeptidkomplex einer grösse von 40 bis 500 nm
World Health Organization DISEASES SUBJECT TO THE REGULATIONS: Notifications received from 2 to 8 October 1998= MALADIES SOUMISES AU RÈGLEMENT: Notifications reçues du 2 au 8 octobre 1998
DE602004031736D1 (de) Verbessertes verfahren für festphasensynthese